Latest News about VTRS
Recent news which mentions VTRS
S&P 500 Losers: 22 Stocks With Negative Returns Over Past 10 Years, And This One's Getting The Boot
August 26, 2025
From Benzinga
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS
August 16, 2025
From Benzinga
From Benzinga
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum
August 12, 2025
From Benzinga
Earnings Scheduled For August 7, 2025
August 07, 2025
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
May 08, 2025
From Benzinga
From Benzinga
Earnings Scheduled For May 8, 2025
May 08, 2025
From Benzinga
Wall Street Mixed Ahead Of Fed Meeting, Alphabet Sinks: What's Driving Markets Wednesday?
May 07, 2025
From Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
May 06, 2025
From Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
April 21, 2025
From Benzinga
From Motley Fool
Viatris Agrees To $335 Million Opioid Settlement Framework
April 07, 2025
From Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
April 04, 2025
From Benzinga
Tesla, Palantir And MicroStrategy Are Among Top 12 Large-Cap Losers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio?
March 02, 2025
From Benzinga
From Benzinga
Earnings Scheduled For February 27, 2025
February 27, 2025
From Benzinga
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
January 06, 2025
From Benzinga
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
December 22, 2024
From Benzinga
Wall Street Closes At Record Highs After Reassurance From Powell: Magnificent 7 Hit $17 Trillion, Treasury Yields Erase Post-Election Spike
November 07, 2024
From Benzinga
Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown
November 07, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.